Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and ...

which is already struggling to establish itself in the COPD market. The drug is positioned as a follow-up product to GSK’s blockbuster Advair/Seretide, but the company is now facing generic ...

Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could ... as the first Advair generic looks to be just around ...

In 2024, the Hatch-Waxman Act continued to play a critical role in the U.S. pharmaceutical landscape, driving the dynamics between ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

“We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

"We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio. "These ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...